AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01055821 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG4040 + SOC
Description: 13 injections
Study NCT01508468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin)
Description: Converting Enzyme inhibitor , Angiotensin II receptor antagonist, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin.
Study NCT01508468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)
Description: NIST and IV infusion of Rituximab 375mg/m² at day (1) and day (8)
Study NCT02161133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy
Description: Problem-Solving Therapy is a treatment approach that teaches patients strategies to address real-life problems.
Study NCT02161133 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Health Education provides didactic information about Gulf War Illness
Study NCT01868022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: docetaxel will be from commercial stock.
Study NCT01868022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: pemetrexed will be from commercial stock
Study NCT01868022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin will be from commercial stock
Study NCT01948440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASI-MV Solutions
Description: The Experimental group will complete the ASI-MV and use the ASI-MV Solutions program for eight 30-minute sessions, followed by monthly booster sessions. The Experimental group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
Study NCT00850278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FLT-PET imaging
Description: Prior to surgical resection, patient will undergo \[11C\]MET PET imaging, \[18F\]FLT PET imaging, MRI, and spectroscopy imaging.
Study NCT00891293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)
Description: Open-label Antara (fenofibrate) + open-label Lovaza (omega-3-acid ethyl esters) \[formerly known as Omacor\]
Study NCT02039479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium Carbonate
Description: Lithium as Add on to every necessary treatment as usual
Study NCT02039479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as ADD-on to every necessary treatment as usual
Study NCT02875171 — intervention group
Intervention type: DRUG
Intervention: Anthracycline administration
Description: Patients suffering from lymphoma or acute leukemia and requiring anthracycline administration were included
Study NCT02469974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RUXOLITINIB / INC 424
Description: Administered orally 5-20 mg twice daily x 16 weeks of therapy prior to attempted peripheral blood stem cells (PBSC) collection, during the collection and rest period and 3 months of therapy after high dose chemotherapy (HDC).
Study NCT02469974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Peripheral blood stem cells (PBSC) will be mobilized with filgrastim 10 mcg/kg/day IV
Study NCT02469974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Conditioning for autologous Hematopoeitic Stem Cell Transplantation (HSCT) will consist of IV busulfan 2.0 mg/KBW once daily x 4 for days -5 to -2
Study NCT03304509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telematic follow-up
Description: Telematic follow-up by using a platform with videoconference
Study NCT01439100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone/Naloxone Prolonged Release tablets
Study NCT01439100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dummy tablet
Study NCT02752256 — intervention group
Intervention type: DRUG
Intervention: Tissue Plasminogen Activator
Study NCT02385526 — intervention group
Intervention type: DEVICE
Intervention: Vagus Nerve Stimulation Therapy
Description: Stimulation of the left tenth cranial nerve via VNS Therapy
Study NCT03753997 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment by a diabetes educated psychologist
Description: Patients will meet a diabetes educated psychologist. There will be a minimum of 5 meetings during the first 3 months and then in the following 6 months there will be a minimum of 2 meetings. More meetings will be scheduled if needed.
Study NCT04038151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Leg
Description: The Hybrid Knee uses an actively variable transmission in combination of a passive spring/damper system. This allows the motor torque output to be adapted to the requirements of active dynamic tasks - changing the effective transmission ration from zero (fully passive) for level ground walking to a maximum value (fully active) for sit-to-stand transfers. This provides physiological knee torque and speed with a small motor and primary transmission system while also maximizing electrical efficiency, which minimized battery weight. The knee prototype weights 1.7kg. The Semi-active ankle can actively reposition during non-weight bearing phases of gait and uses a non back driveable transmission to maintain its set point during weight bearing activities.
Study NCT04038151 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prescribed Passive Prosthesis
Description: Participants will participate in training sessions of community skills and advanced ambulation training for their home, prescribed passive prosthesis.
Study NCT02362906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiyanping injection
Description: ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection
Study NCT02362906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: wind-heat formula granules
Description: children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
Study NCT02362906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phlegm-heat formula granules
Description: children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
Study NCT02362906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fu-xiong San
Description: external application; 8-10 cm wide, 0.3-0.5 cm thick;10 mins for patient aged 1 to 3-year old; 15 mins for those aged 3 to 5-year old; once daily
Study NCT02362906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: second generation cephalosporin
Study NCT02362906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: ivd. 30 mg/(kg•d), plus 5% Glucose Injection, 80 to 500 ml, ivd. Once a day injection
Study NCT02362906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: ivd. 10 mg/(kg•d), plus 5% Glucose Injection, 100 to 500 ml, ivd. Once a day injection
Study NCT02087059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study NCT03112018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: data strengthening
Description: Data strengthening: initial training, monthly data collection and feedback on data quality, access to dashboards, periodic Data Quality Assessments
Study NCT03112018 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: data strengthening
Description: Data strengthening: initial training, monthly data collection and feedback on data quality, access to dashboards, periodic Data Quality Assessments
Study NCT03112018 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: modified Safe childbirth checklist - control
Description: modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, limited feedback and mentoring on its use
Study NCT03112018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified Safe childbirth checklist - enhanced
Description: modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, ongoing intensive feedback and mentoring on its use
Study NCT03112018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRONTO training
Description: Health provider training (PRONTO): initial 2-days modular training followed by a 6-week mentoring sessions (Kenya) or periodic modular refreshers and supplemental mentoring (Uganda), each over a 9-12 month period
Study NCT03112018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QI cycles
Description: Quality Improvement Cycles (QI): facility teams performing PDSA cycles with mentoring support and twice annual Learning Collaborative sessions, plus opportunities to apply for small amounts of funds to support change efforts
Study NCT05346289 — intervention group
Intervention type: PROCEDURE
Intervention: Elective surgery for intact AAA
Description: Elective surgery including the following modalities: open repair, endovascular repair (EVAR), fenestrated end-vascular repair (FEVAR).
Study NCT00733538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zometa
Description: patients receiving treatment during their follow-up
Study NCT02607995 — intervention group
Intervention type: BEHAVIORAL
Intervention: Behavioral standardized manual-based multidisciplinary routine care
Description: Behavioral standardized manual-based multidisciplinary routine care (lifestyle intervention). Six sessions offered over the course of three to six months with a focus on weight loss. The topics 1) causes, consequences and treatment options of obesity, 2) nutrition, 3) eating behaviors and problem solving strategies, 4) self esteem and emotional eating, 5) exercise, and 6) use of media will be covered.
Study NCT04702568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX9930
Description: BCX9930 for oral administration
Study NCT04702568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Administered at stable dose at the time of study entry
Study NCT04702568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Administered at stable dose at the time of study entry
Study NCT04336436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: Mindfulness training
Study NCT04336436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional consult
Description: Nutrition counseling and development of a personalized nutrition plan
Study NCT03625570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Power training combined with interval treadmill training
Description: Training will consist of unilateral and bilateral leg presses, targeting the quadriceps, hip extensors, and plantarflexors according to resistance training guidelines for muscle power training. The interval treadmill training portion will include short-bursts (30 seconds) of high speed walking intervals alternating with 30 seconds of low to moderate speed walking for a total of 30 minutes. Participants will train 3 x per week for 8 weeks. Total duration of each session will be approximately 1 hour.
Study NCT03625570 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength training combined with traditional treadmill training
Description: Training will consist of unilateral and bilateral leg presses, targeting the quadriceps, hip extensors, and plantarflexors following the dosing and resistance training guidelines for muscle strength. Traditional treadmill training will consist of walking at steady-state speeds for 30 minutes. Participants will train 3 x per week for 8 weeks. Total duration of each session will be approximately 1 hour.
Study NCT03640208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education presented by trained caregiver
Description: After participants complete the Pre-test, an educational session will be presented by a trained caregiver, delivered in a lecture-style manner with Power Point projection of educational material. The slides in this presentation will be scripted to mitigate variability among different presenters. Topics addressed in the presentation include: CRC basics (including brief anatomy), data on disparity, risk factors, screening modalities, preventative measures, population disparities of CRC, colonoscopy exam and other screening tests. The emphasis will be on CRC risks factors and prevention. All required information that is needed to correctly answer post-test questions is embedded within the presentation.
Study NCT04632927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
Study NCT04632927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
Study NCT02618967 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 570
Description: 7 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers.
Study NCT02618967 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AMG 570 Matching Placebo
Description: Placebo administered as single dose subcutaneous in healthy volunteers.
Study NCT03154216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 90 minutes of moderate-intensity walking exercise on a treadmill
Study NCT03154216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drink
Description: Beverage to be consumed after exercise
Study NCT03340519 — intervention group
Intervention type: DEVICE
Intervention: MR Imaging
Description: Novel MR imaging will be performed to provide bowel anatomic and functional data
Study NCT02968784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate MRgFUS
Description: ExAblate treatment of prostate cancer less than or equal to Grade 7
Study NCT01915615 — intervention group
Intervention type: OTHER
Intervention: None - this is an observational study
Description: None - this is an observational study
Study NCT03818412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Archival tumor tissue collection and blood draws
Description: Archival tumor tissue will be collected for testing of circulating tumor DNA. Blood draws will be taken for testing of circulating tumor DNA.
Study NCT01483924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apo805K1
Description: Sequential parallel dose escalation.
Study NCT05349344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic circuit training
Description: Aerobic Exercise Training, 3 times a week for 8 weeks, (Tuesday, Thursday \& Saturday, 24 sessions Total) 30 min each time, at 60-80 % of HR max (moderate intensity).
Study NCT05349344 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Outdoor walk
Description: 30minutes Walking outside below 40% of HR max for 2 months.(3 times per week for 8 weeks).
Study NCT03602118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenobarbital Sodium Injection
Description: Phenobarbitone Inj, Phenobarbitone SOD, Phenobarbitone Sodium
Study NCT02496624 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cone Beam CT localization and placement of microcoil
Description: Cone Beam CT localization and placement of microcoil
Study NCT02975973 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: transcranial direct current stimulation (tDCS) is a safe, noninvasive, weak electrical current delivery that stimulates brain function. It is a novel therapeutic for cognition in schizophrenia.
Study NCT02975973 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: transcranial direct current stimulation (tDCS) is a safe, noninvasive, weak electrical current delivery that stimulates brain function. It is a novel therapeutic for cognition in schizophrenia.
Study NCT03923348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leva device
Description: The leva® Pelvic Digital Health System by Renovia Inc is a novel tool for subjects with urinary incontinence to train and strengthen pelvic floor muscles via directional mechano-transductive feedback on performance in the privacy of their own homes.
Study NCT00067015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Study NCT00067015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Study NCT00067015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assessment of therapy complications
Study NCT00067015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT00067015 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT03232970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full Plate Diet
Description: 12 weekly sessions on how to incorporate more fiber in the diet.
Study NCT02429765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACL/FOR
Study NCT02429765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00538135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Study NCT00538135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Standard National Health Service treatment as usual for borderline personality disorder
Study NCT00538135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Standard National Health Service treatment as usual for borderline personality disorder
Study NCT01273454 — intervention group
Intervention type: DRUG
Intervention: OROS Hydromorphone
Description: 8,16, 32 mg once a day for 4 weeks
Study NCT02369094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS centers. The caregiver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
Study NCT02369094 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: acupressure
Description: A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS centers. The caregiver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
Study NCT02264704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity exericse
Description: Participants will exercise at high intensity (70% VO2 peak) intermittently (30 seconds on, 30 seconds off) for 15 minutes, twice weekly for 15 weeks. Workload may increase as the study progresses based on heart rate response.
Study NCT02264704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity exericse
Description: Participants exercise at moderate intensity (35% VO2 peak) continuously for 15 minutes, twice weekly for 15 weeks. Workload may increase as the study progresses based on heart rate response.
Study NCT03605095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroglycerin
Description: Vasodilatator solution is dropped on the gingiva.
Study NCT01603264 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05280014
Description: Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
Study NCT01603264 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
Study NCT01603264 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
Study NCT01311960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab eye drop 0.05%
Description: bevacizumab eye drop 0.05% will apply 4 times a day for 3 months
Study NCT01311960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline 0.9%
Description: normal saline eye drop 0.9% will apply 4 times a day for 3 months.
Study NCT02610348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines
Description: Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study
Study NCT02610348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-HB-IPV and Pneumococcal polysaccharide vaccines
Description: Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study